secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008231
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics Q1 net loss $69.2M; cash $1.2B; pipeline on track for H2 2022
-------------------------------------------------------------------------------

- Net loss $69.2M ($1.01 per share) vs $201.6M ($3.35) in Q1 2021 due to prior-year in-process R&D charge.
- Cash, equivalents and marketable securities $1.2B as of March 31, 2022 (vs $965.6M at Dec 31, 2021).
- R&D expenses $65.4M (excl. $155M Guide Therapeutics acquisition cost in Q1 2021); G&A $19.2M.
- BEAM-101 enrollment, BEAM-102 IND, and BEAM-201 IND all on track for second half of 2022.
- Initiated AUNT natural history study in sickle cell trait; appointed Manmohan Singh to exec leadership and Anne Marie Woodland as head of regulatory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022008231/0000950170-22-008231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022008231/beam-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer